Limits...
Inhibition of interleukin-1beta-stimulated dedifferentiation of chondrocytes via controlled release of CrmA from hyaluronic acid-chitosan microspheres.

Ma BL, Zhou PH, Xie T, Shi L, Qiu B, Wang Q - BMC Musculoskelet Disord (2015)

Bottom Line: The CrmA release kinetics were characterized by an initial burst release, which was reduced to a linear release over ten days.The production of GAG and the expression of type II collagen, aggrecan significantly increased compared with the control group, while the expression of collagen I and IL-1β decreased.The suppression of inflammatory cytokines activity within the joint might be one important mechanism of the action of the microspheres in the treatment of OA.

View Article: PubMed Central - PubMed

Affiliation: Department of Laboratory, Qilu Hospital of Shandong University, 250012, Jinan, China. ma_bella@163.com.

ABSTRACT

Background: The previous studies indicated that CrmA could ameliorate the interleukin-1β induced osteoarthritis. In this study, we investigated the controlled-released cytokine response modifier A (CrmA) from hyaluronic acid (HA)-chitosan (CS) microspheres to improve interleukin-1β (IL-1β)-stimulated dedifferentiation of chondrocytes.

Methods: A rat model of osteoarthritis (OA) in vitro was established using 10 ng/ml IL-1β as modulating and chondrocytes inducing agent. HA-CS-CrmA microspheres were added to the medium after IL-1β was co-cultured with freshly isolated rat chondrocytes for 48 hours. The chondrocytes viability and glycosaminoglycan (GAG) content were determined. The level of CrmA secreted was detected by Enzyme-Linked Immunosorbent Assay (ELISA). The protein levels of type II collagen, aggrecan, collagen I and IL-1β were detected using western blotting analyses.

Results: The CrmA release kinetics were characterized by an initial burst release, which was reduced to a linear release over ten days. The production of GAG and the expression of type II collagen, aggrecan significantly increased compared with the control group, while the expression of collagen I and IL-1β decreased.

Conclusions: This study demonstrated that HA-CS microspheres containing CrmA could attenuate the degeneration of articular cartilage by maintaining the phenotype of chondrocytes during culture expansion. The suppression of inflammatory cytokines activity within the joint might be one important mechanism of the action of the microspheres in the treatment of OA.

No MeSH data available.


Related in: MedlinePlus

Western blot analyses for type II collagen, aggrecan I, collagen and IL-1beta. Type II collagen and aggrecan expression was substantially restored by HA-CS-CrmA microspheres. However, collagen I and IL-1β were decreased in HA-CS-CrmA group and CS- CrmA group compared with the OA group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4384377&req=5

Fig5: Western blot analyses for type II collagen, aggrecan I, collagen and IL-1beta. Type II collagen and aggrecan expression was substantially restored by HA-CS-CrmA microspheres. However, collagen I and IL-1β were decreased in HA-CS-CrmA group and CS- CrmA group compared with the OA group.

Mentions: As can be seen in Figure 5, type II collagen and aggrecan expression by chondrocyte, which had been significantly reduced by IL-1β exposure, was substantially restored by HA-CS-CrmA microspheres. However, collagen I and IL-1β decreased in HA-CS-CrmA group and CS- CrmA group compared with the OA group. The results indicated that the chondrocyte changed to normalization when treated with microspheres, especially in the presence of CrmA.Figure 5


Inhibition of interleukin-1beta-stimulated dedifferentiation of chondrocytes via controlled release of CrmA from hyaluronic acid-chitosan microspheres.

Ma BL, Zhou PH, Xie T, Shi L, Qiu B, Wang Q - BMC Musculoskelet Disord (2015)

Western blot analyses for type II collagen, aggrecan I, collagen and IL-1beta. Type II collagen and aggrecan expression was substantially restored by HA-CS-CrmA microspheres. However, collagen I and IL-1β were decreased in HA-CS-CrmA group and CS- CrmA group compared with the OA group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4384377&req=5

Fig5: Western blot analyses for type II collagen, aggrecan I, collagen and IL-1beta. Type II collagen and aggrecan expression was substantially restored by HA-CS-CrmA microspheres. However, collagen I and IL-1β were decreased in HA-CS-CrmA group and CS- CrmA group compared with the OA group.
Mentions: As can be seen in Figure 5, type II collagen and aggrecan expression by chondrocyte, which had been significantly reduced by IL-1β exposure, was substantially restored by HA-CS-CrmA microspheres. However, collagen I and IL-1β decreased in HA-CS-CrmA group and CS- CrmA group compared with the OA group. The results indicated that the chondrocyte changed to normalization when treated with microspheres, especially in the presence of CrmA.Figure 5

Bottom Line: The CrmA release kinetics were characterized by an initial burst release, which was reduced to a linear release over ten days.The production of GAG and the expression of type II collagen, aggrecan significantly increased compared with the control group, while the expression of collagen I and IL-1β decreased.The suppression of inflammatory cytokines activity within the joint might be one important mechanism of the action of the microspheres in the treatment of OA.

View Article: PubMed Central - PubMed

Affiliation: Department of Laboratory, Qilu Hospital of Shandong University, 250012, Jinan, China. ma_bella@163.com.

ABSTRACT

Background: The previous studies indicated that CrmA could ameliorate the interleukin-1β induced osteoarthritis. In this study, we investigated the controlled-released cytokine response modifier A (CrmA) from hyaluronic acid (HA)-chitosan (CS) microspheres to improve interleukin-1β (IL-1β)-stimulated dedifferentiation of chondrocytes.

Methods: A rat model of osteoarthritis (OA) in vitro was established using 10 ng/ml IL-1β as modulating and chondrocytes inducing agent. HA-CS-CrmA microspheres were added to the medium after IL-1β was co-cultured with freshly isolated rat chondrocytes for 48 hours. The chondrocytes viability and glycosaminoglycan (GAG) content were determined. The level of CrmA secreted was detected by Enzyme-Linked Immunosorbent Assay (ELISA). The protein levels of type II collagen, aggrecan, collagen I and IL-1β were detected using western blotting analyses.

Results: The CrmA release kinetics were characterized by an initial burst release, which was reduced to a linear release over ten days. The production of GAG and the expression of type II collagen, aggrecan significantly increased compared with the control group, while the expression of collagen I and IL-1β decreased.

Conclusions: This study demonstrated that HA-CS microspheres containing CrmA could attenuate the degeneration of articular cartilage by maintaining the phenotype of chondrocytes during culture expansion. The suppression of inflammatory cytokines activity within the joint might be one important mechanism of the action of the microspheres in the treatment of OA.

No MeSH data available.


Related in: MedlinePlus